[Efficacy of arbekacin, a new aminoglycoside antibiotic, in surgical patients with MRSA infections].
The clinical efficacy of a new aminoglycoside antibiotic, arbekacin (ABK), was studied in surgical patients who had been infected with methicillin-resistant Staphylococcus aureus (MRSA). Six cases of pneumonia, 2 of wound infections and 2 of intra-abdominal infections were treated by ABK alone or ABK together with beta-lactam antibiotics such as imipenem/cilastatin or cefotiam. The overall clinical efficacies against these MRSA infections were excellent in one case, good in 6 and poor in 3. In six cases treated by ABK alone, good clinical responses were obtained in 4 cases. Among 4 cases that received combination therapy with ABK, good responses were obtained in 3 cases. No adverse reactions were found in ABK monotherapy or in combined therapy. These data suggested that ABK is an effective antibiotic on surgical infections caused by MRSA.
Ishikawa
S
S
First Department of Surgery, Nagoya City University, Medical School.
Yura
J
J
Shinagawa
N
N
Mizuno
A
A
Mashita
K
K
Hori
K
K
D000368:Aged; D000369:Aged, 80 and over; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D015310:Cefotiam / Q000627:therapeutic use; D015377:Cilastatin / Q000627:therapeutic use; D003982:Dibekacin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use; D008297:Male; D016106:Methicillin Resistance; D011183:Postoperative Complications / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects*; D013530:Surgical Wound Infection / Q000188:drug therapy
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D015377:Cilastatin; D003982:Dibekacin; D015378:Imipenem; D015310:Cefotiam; C031986:arbekacin